April 22nd 2024
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
New Data Solidify Benefit of Loncastuximab Tesirine for Relapsed/Refractory DLBCL
October 1st 2021In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Read More
Roundtable Discussion: Participants Discuss Treatment in Transplant-Ineligible DLBCL
August 20th 2021Grzegorz S. Nowakowski, MD and Stephen D. Smith lead other participants of a Case Based Roundtable event in a discussion around treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.
Read More
Schuster Addresses Treatment Options in DLBCL Treatment
August 17th 2021One year after being diagnosed with CD-10- positive and CD10-positive diffuse large B-cell lymphoma being treated with R-CHOP, and achieving complete remission, a PET/CT scan confirmed relapse in a 74-year-old male patient.
Read More
Polatuzumab Vedotin Combo Improves Outcomes in Previously Untreated DLBCL
August 9th 2021A significantly improved and clinically meaningful progression-free survival was accomplished by combining polatuzumab vedotin and R-CHOP in patients with previously untreated diffuse large B-cell lymphoma compared with R-CHOP alone, according to results of the phase 3 POLARIX trial.
Read More
Combination of Tafasitamab/Lenalidomide Demonstrates Positive Efficacy in DLBCL
August 6th 2021The laboratory results, lymph node biopsy, imaging studies and other information of a 75-year-old patient with diffuse large B-cell lymphoma were brought into consideration during a Targeted Oncology Case-Based Roundtable discussion around treatment with tafasitamab and lenalidomide (Revlimid).
Read More
Matthew A. Lunning, DO began a Case-Based Roundtable event by asking a group of oncologists how diffuse large b-cell lymphoma in handling in their practices. The responses varied, considering some of the oncologists worked in academic centers and some worked in the community setting.
Read More
Options for Second-Line Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 23rd 2021Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.
Watch
Tafasitamab/Lenalidomide Combo Demonstrates Favorable Efficacy in DLBCL
July 21st 2021In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.
Read More
Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL
July 15th 2021Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
Watch
Phase 3 Front-MIND Trial Initiated to Explore Tafasitamab Triplet in DLBCL
June 16th 2021A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Real World Data Show Patients with DLBCL Receive Axi-Cel/Tisa-Cel Prior to Treatment Failure
June 13th 2021Real world data looking at the use of the recently approved CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel show that patients are receiving it prior to failing treatments and that 1 in 6 patients were experiencing relapse after treatment.
Read More
Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCL
June 12th 2021Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.
Read More